Semaglutide guidelines based on BMI may exclude at-risk Indians
This image was generated by AI and may not depict real events.
A recent study published in The New England Journal of Medicine found that semaglutide reduces major cardiovascular events by 20% in adults with a BMI of 27 or higher and pre-existing cardiovascular disease. However, applying this BMI threshold in India may exclude patients at risk due to differences in body composition and disease risk factors.
The SELECT trial enrolled 17,604 participants and tracked outcomes over nearly 40 months. The study found that once-weekly semaglutide reduced major cardiovascular events by 20%. This treatment may not be available to at-risk Indians due to the BMI threshold. The trial was led by A. Michael Lincoff and published in 2023. Applying this threshold in India could exclude patients who need the treatment. This is a concern for public health experts like Aditi Kantipuly.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.